The biggest barriers to stopping the transmission of HIV are both the large population of infected people not receiving treatment and the lack of pre-exposure prophylaxis for high-risk individuals, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
The biggest barriers to stopping the transmission of HIV are both the large population of infected people not receiving treatment and the lack of pre-exposure prophylaxis for high-risk individuals, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Transcript
What are the barriers to preventing the transmission of HIV/AIDS?
I think as we learn more and do more studies on the use of pre-exposure prophylaxis, that the data’s going to be overwhelming. I mean, we’re really only two, three years into these studies and I think it does take some time. Also, the cost needs to decrease. But I think as we do more studies, show more efficacy, and get better acceptance in the countries that have been reticent to accept it, I think we’ll make some headway. So that’s number one.
The second means of prevention is treating the HIV-infected person. So, how are we doing with that? Right now, probably less than 45 percent of the world’s HIV population is under treatment and virally suppressed. So that’s good news, that those individuals are non-infectious or less infectious to their sexual partners, but that means 55 percent of the world’s population is untreated. And that is probably one of the biggest barriers.
It’s getting people to, one, be screened and be tested and to know they’re infected, two, to get them into care, and three, to get them put onto anti-retroviral drugs once in care, and then fourth and lastly, make sure they’re suppressed. If they’re virally suppressed, they’re non-infectious. There’s really been almost no transmissions of individuals who have a completely suppressed viral load of HIV. So I would say the two biggest barriers right now in prevention is not enough people on treatment that need to be on treatment and virally suppressed, and two, the high-risk individuals not getting pre-exposure prophylaxis, which can block HIV acquisition.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More